Program - Saturday, May 12

Print
Please click on the relevant day to view the applicable detailed program.

 
Saturday, May 12
SATURDAY 12 MAY, 2018
 
Plenary Hall
09:00-10:30 Plenary Session 7 | Diabetes and Obesity Tomorrow
09:00-09:05  Chairpersons: Teng Weiping, China and Ning Guang, China
09:05-09:25 The situation of type 1 diabetes in China: Weng Jianping, China 
09:25-09:55 Revisiting some of the dogmas of obesity and insulin resistance associated type 2 diabetes: Marc Prentki, Canada
 09:55-10:20  AI in the management of diabetes: Practice and future: Ning Guang, China
10:20-10:30  Discussion
10:30-10:50
Coffee Break
 
Hall A
10:50-12:20 Session 8 | New Players In T2DM
10:50-10:55 Chairperson: Itamar Raz, Israel, Zhu Jun, China and Chen Bing, China
  NAFLD/NASH epidemic
10:55-11:15 Yes: Gao Xin, China
11:15-11:35 No: Itamar Raz, Israel
  Metabolic surgery
11:35-11:55  Yes: Luc Van Gaal, Belgium
11:55-12:10  No:  Zhang Yifei, China
12:10-12:20 Discussion
 
Hall B
10:50-12:20 Session 9 | Treatment Evolution In Insulin Therapy
10:50-10:55  Chairpersons: Guo Lixin, China, Qin Yinfen, China and Philip Home, UK 
10:55-11:15  Combination therapy: Yang Tao, China
11:15-11:35 New insulins: Philip Home, UK
11:35-11:55 Increased prevalence of masked hypertension in diabetes: Michael Bursztyn, Israel
11:55-11:20 Discussion
 
Hall C
10:50-12:20 Session 10 | The Preferred Choice of Whole-Journey in Diabetes Management
10:50-10:55 Chairperson: Wang Weiqing, China 
10:55-11:20  Choosing diabetic drugs under multiple considerations: Zhang Junqung, China 
11:20-11:45  Lasting charms - Optimal management of hypoglycemia and insulin therapy: Li Qang, China 
11:45-12:10  GLP-1 RA - New choice for diabetes individualized therapy 
12:10-12:20  Discussion  
12:20-12:30
Lunch Box Pick Up
 
Hall A
12:30-13:30 Industry Lunch Symposium J
 
Hall B
12:30-13:30 Industry Lunch Symposium K
 
Hall C
12:30-13:30 Industry Lunch Symposium L
 
Hall A
13:30-15:00
Session 11 | Fighting Obesity
13:30-13:35  Chairpersons: Luc Van Gaal, Belgium Qing Guijun, China and Ji Qiuhe, China
13:35-13:55  What’s new – Same as Europe? Zou Dajin, China
13:55-14:15  Obesity: a disease or a condition? Hong Jie, China
14:15-14:35  Pharmacological and non-pharmacological treatment of obesity: Luc Van Gaal, Belgium
14:35-15:00 
Discussion
 
Hall B
13:30-15:00
Session 12 | Diabetes and Heart Failure
13:35-13:55  Chairperson: Mikhail Kosiborod, USA , Ning Guang, China and Zhang Junqing, China
13:35-13:55  Diabetic cardiomyopathy: Mikhail Kosiborod, USA
13:55-14:10  KB and heart function: Zhang Yun, China
14:10-14:25
HF and anti-hyperglycemic drugs: Eberhard Standl, Germany
14:25-14:40  Does treating obstructive sleep apnea help to treat diabetes: Benjamin Fox, Israe 
14:40-15:00 
Discussion
 
Hall C
13:30-15:00
Session 13 | Innovations in Diabetes
13:30-13:35  Chairpersons: Yang Liyong, China and Zhao Zhigang, China
13:35-13:55  Oral Insulin: Wang Weiqing, China
13:55-14:10 Physical activity and type 2 diabetes: Prevention, remission & management: Bi Yufang, China 
14:10-14:25 Dorzagliatin (HMS5552), a novel glucokinase activator, as monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomized, double-blind, placebo-controlled, phase II proof of concept study: Zhu Dalong, China
14:25-14:40 Entry and exit from the glycerolipid/fatty acid cycle: targets for obesity and diabetes: Marc Prentki, Canada
14:40-15:00  Discussion 
 
Plenary Hall
15:00-15:45
Closing Plenary Session 14| Key Note Lecture
  Chairperson: Ning Guang, China
SGLT2 CVOT:From RWE to RCT: how to look at CVD REAL and DECLARE? Itamar Raz, Israel
15:45-16:00 Closing Ceremony